EO-2002 is under clinical development by Emmecell and currently in Phase I for Corneal Edema. According to GlobalData, Phase I drugs for Corneal Edema does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EO-2002 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EO-2002 overview
EO-2002 is under development for the treatment of corneal edema and cataract. It is administered through intracameral route. The therapeutic candidate comprises of human corneal endothelial cells (HCECs) being developed based on magnetic cell delivery (MCD) nanoparticle platform.
Emmecell overview
Emmecell is a biotechnology company developing regenerative medicine using cell therapies focused on ophthalmic indications. The company is headquartered in Menlo Park, California, the US.
For a complete picture of EO-2002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
